Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 426

1.

Autophagy-Independent Functions of the Autophagy Machinery.

Galluzzi L, Green DR.

Cell. 2019 Jun 13;177(7):1682-1699. doi: 10.1016/j.cell.2019.05.026. Review.

PMID:
31199916
2.

Heterogeneous cellular effects of α-ketoglutarate esters.

Galluzzi L.

Aging (Albany NY). 2019 Jun 11. doi: 10.18632/aging.102028. [Epub ahead of print] No abstract available.

3.

Trial watch: dietary interventions for cancer therapy.

Lévesque S, Pol JG, Ferrere G, Galluzzi L, Zitvogel L, Kroemer G.

Oncoimmunology. 2019 Apr 3;8(7):1591878. doi: 10.1080/2162402X.2019.1591878. eCollection 2019. Review.

4.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review.

5.

TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer.

Fucikova J, Rakova J, Hensler M, Kasikova L, Belicová L, Hladikova K, Truxova I, Skapa P, Laco J, Pecen L, Praznovec I, Halaska MJ, Brtnicky T, Kodet R, Fialová A, Pineau J, Gey A, Tartour E, Ryska A, Galluzzi L, Spisek R.

Clin Cancer Res. 2019 May 10. pii: clincanres.4175.2018. doi: 10.1158/1078-0432.CCR-18-4175. [Epub ahead of print]

PMID:
31076549
6.

Metabolic enzymes expressed by cancer cells impact the immune infiltrate.

Stoll G, Kremer M, Bloy N, Joseph A, Castedo M, Meurice G, Klein C, Galluzzi L, Michels J, Kroemer G.

Oncoimmunology. 2019 Mar 30;8(6):e1571389. doi: 10.1080/2162402X.2019.1571389. eCollection 2019.

PMID:
31069148
7.

Stress responses in stromal cells and tumor homeostasis.

Vitale I, Manic G, Galassi C, Galluzzi L.

Pharmacol Ther. 2019 Apr 16. pii: S0163-7258(19)30061-0. doi: 10.1016/j.pharmthera.2019.04.004. [Epub ahead of print] Review.

PMID:
30998941
8.

Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate.

Sica V, Bravo-San Pedro JM, Izzo V, Pol J, Pierredon S, Enot D, Durand S, Bossut N, Chery A, Souquere S, Pierron G, Vartholomaiou E, Zamzami N, Soussi T, Sauvat A, Mondragón L, Kepp O, Galluzzi L, Martinou JC, Hess-Stumpp H, Ziegelbauer K, Kroemer G, Maiuri MC.

Cell Rep. 2019 Apr 16;27(3):820-834.e9. doi: 10.1016/j.celrep.2019.03.058.

9.

Cancer Cells Thrive on Stress.

Galluzzi L, Kroemer G.

Trends Cell Biol. 2019 Jun;29(6):447-449. doi: 10.1016/j.tcb.2019.03.005. Epub 2019 Apr 5.

PMID:
30962044
10.

Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity.

Vanpouille-Box C, Galluzzi L.

Int Rev Cell Mol Biol. 2019;345:ix-xiii. doi: 10.1016/S1937-6448(19)30041-3. No abstract available.

PMID:
30904197
11.

Born to Kill: NK Cells Go to War against Cancer.

Wennerberg E, Galluzzi L.

Trends Cancer. 2019 Mar;5(3):143-145. doi: 10.1016/j.trecan.2018.12.005. Epub 2019 Jan 12.

PMID:
30898260
12.

Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity.

Vanpouille-Box C, Galluzzi L.

Int Rev Cell Mol Biol. 2019;344:xi-xv. doi: 10.1016/S1937-6448(19)30030-9. No abstract available.

PMID:
30798992
13.

Etiological involvement of CFTR in apparently unrelated human diseases.

Galluzzi L, Kroemer G.

Mol Cell Oncol. 2018 Dec 27;6(1):1558874. doi: 10.1080/23723556.2018.1558874. eCollection 2019. No abstract available.

PMID:
30788425
14.

Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy.

Vitale I, Sistigu A, Manic G, Rudqvist NP, Trajanoski Z, Galluzzi L.

Trends Cell Biol. 2019 May;29(5):396-416. doi: 10.1016/j.tcb.2019.01.003. Epub 2019 Feb 11. Review.

PMID:
30765144
15.

Exosome secretion by Leishmania infantum modulate the chemotactic behavior and cytokinic expression creating an environment permissive for early infection.

Castelli G, Bruno F, Saieva L, Alessandro R, Galluzzi L, Diotallevi A, Vitale F.

Exp Parasitol. 2019 Mar;198:39-45. doi: 10.1016/j.exppara.2019.01.014. Epub 2019 Feb 1.

PMID:
30716304
16.

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C.

J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3.

17.

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C.

J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5.

18.

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.

Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Pabla S, Conroy JM, Glenn ST, DeFedericis HT, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Kanehira K, Lenzo FL, Frederick P, Lele S, Galluzzi L, Kuvshinoff B, Morrison C.

BMC Med Inform Decis Mak. 2019 Jan 18;19(1):14. doi: 10.1186/s12911-019-0743-x.

19.

Metformin prevents cell tumorigenesis through autophagy-related cell death.

De Santi M, Baldelli G, Diotallevi A, Galluzzi L, Schiavano GF, Brandi G.

Sci Rep. 2019 Jan 11;9(1):66. doi: 10.1038/s41598-018-37247-6.

20.

T Cells: Friends and Foes.

Rudqvist NP, Galluzzi L.

Int Rev Cell Mol Biol. 2019;342:xi-xiv. doi: 10.1016/S1937-6448(19)30009-7. No abstract available.

PMID:
30635096
21.

Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate.

Galluzzi L, Kroemer G.

Oncoimmunology. 2018 Oct 16;7(12):e1528815. doi: 10.1080/2162402X.2018.1528815. eCollection 2018.

PMID:
30524910
22.

Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018. Review.

PMID:
30524908
23.

Trial watch: Peptide-based vaccines in anticancer therapy.

Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018. Review.

24.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

G Pol J, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, R Clements D, Fahrner JE, Fend L, C Bell J, L Mossman K, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Review.

PMID:
30524901
25.

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.

George S, Papanicolau-Sengos A, Lenzo FL, Conroy JM, Nesline M, Pabla S, Glenn ST, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Galluzzi L, Morrison C.

Oncoimmunology. 2018 May 29;7(12):e1460298. doi: 10.1080/2162402X.2018.1460298. eCollection 2018.

26.

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.

Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T, Salkova E, Rob L, Kodet R, Goc J, Sautes-Fridman C, Fridman WH, Ryska A, Galluzzi L, Spisek R, Fucikova J.

J Immunother Cancer. 2018 Dec 4;6(1):139. doi: 10.1186/s40425-018-0446-3.

27.

Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels and tumor growth.

Marchi S, Corricelli M, Branchini A, Vitto VAM, Missiroli S, Morciano G, Perrone M, Ferrarese M, Giorgi C, Pinotti M, Galluzzi L, Kroemer G, Pinton P.

EMBO J. 2019 Jan 15;38(2). pii: e99435. doi: 10.15252/embj.201899435. Epub 2018 Nov 30.

PMID:
30504268
28.

Exploiting genetic polymorphisms in metabolic enzymes for rapid screening of Leishmania infantum genotypes.

Ceccarelli M, Diotallevi A, Andreoni F, Vitale F, Galluzzi L, Magnani M.

Parasit Vectors. 2018 Nov 1;11(1):572. doi: 10.1186/s13071-018-3143-7.

29.

Linking cellular stress responses to systemic homeostasis.

Galluzzi L, Yamazaki T, Kroemer G.

Nat Rev Mol Cell Biol. 2018 Nov;19(11):731-745. doi: 10.1038/s41580-018-0068-0. Review.

30.

The hallmarks of successful anticancer immunotherapy.

Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A.

Sci Transl Med. 2018 Sep 19;10(459). pii: eaat7807. doi: 10.1126/scitranslmed.aat7807. Review.

PMID:
30232229
31.

WNT Signaling in Cancer Immunosurveillance.

Galluzzi L, Spranger S, Fuchs E, López-Soto A.

Trends Cell Biol. 2019 Jan;29(1):44-65. doi: 10.1016/j.tcb.2018.08.005. Epub 2018 Sep 13. Review.

PMID:
30220580
32.

Cytosolic DNA Sensing in Organismal Tumor Control.

Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L.

Cancer Cell. 2018 Sep 10;34(3):361-378. doi: 10.1016/j.ccell.2018.05.013. Epub 2018 Jun 28. Review.

PMID:
30216189
33.

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles.

Bonora M, Wieckowski MR, Sinclair DA, Kroemer G, Pinton P, Galluzzi L.

Nat Rev Cardiol. 2019 Jan;16(1):33-55. doi: 10.1038/s41569-018-0074-0. Review.

PMID:
30177752
34.

Modeling Tumor Immunology and Immunotherapy in Mice.

Buqué A, Galluzzi L.

Trends Cancer. 2018 Sep;4(9):599-601. doi: 10.1016/j.trecan.2018.07.003. Epub 2018 Aug 3.

PMID:
30149876
35.

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Feb 15;7(6):e1433982. doi: 10.1080/2162402X.2018.1433982. eCollection 2018. Review.

36.

Leishmania Infection Induces MicroRNA hsa-miR-346 in Human Cell Line-Derived Macrophages.

Diotallevi A, De Santi M, Buffi G, Ceccarelli M, Vitale F, Galluzzi L, Magnani M.

Front Microbiol. 2018 May 17;9:1019. doi: 10.3389/fmicb.2018.01019. eCollection 2018.

37.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.

Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.

J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.

38.

Real-time PCR applications for diagnosis of leishmaniasis.

Galluzzi L, Ceccarelli M, Diotallevi A, Menotta M, Magnani M.

Parasit Vectors. 2018 May 2;11(1):273. doi: 10.1186/s13071-018-2859-8. Review.

39.

Oncogene-induced senescence and tumour control in complex biological systems.

Galluzzi L, Vitale I.

Cell Death Differ. 2018 Jun;25(6):1005-1006. doi: 10.1038/s41418-018-0102-y. Epub 2018 Apr 17. No abstract available.

40.

SnapShot: CGAS-STING Signaling.

Galluzzi L, Vanpouille-Box C, Bakhoum SF, Demaria S.

Cell. 2018 Mar 22;173(1):276-276.e1. doi: 10.1016/j.cell.2018.03.015. Review.

41.

BAX and BAK at the Gates of Innate Immunity.

Galluzzi L, Vanpouille-Box C.

Trends Cell Biol. 2018 May;28(5):343-345. doi: 10.1016/j.tcb.2018.02.010. Epub 2018 Mar 16.

PMID:
29555208
42.

The autophagic network and cancer.

Rybstein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L.

Nat Cell Biol. 2018 Mar;20(3):243-251. doi: 10.1038/s41556-018-0042-2. Epub 2018 Feb 23. Review.

PMID:
29476153
43.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

44.

Guidelines and recommendations on yeast cell death nomenclature.

Carmona-Gutierrez D, Bauer MA, Zimmermann A, Aguilera A, Austriaco N, Ayscough K, Balzan R, Bar-Nun S, Barrientos A, Belenky P, Blondel M, Braun RJ, Breitenbach M, Burhans WC, Büttner S, Cavalieri D, Chang M, Cooper KF, Côrte-Real M, Costa V, Cullin C, Dawes I, Dengjel J, Dickman MB, Eisenberg T, Fahrenkrog B, Fasel N, Fröhlich KU, Gargouri A, Giannattasio S, Goffrini P, Gourlay CW, Grant CM, Greenwood MT, Guaragnella N, Heger T, Heinisch J, Herker E, Herrmann JM, Hofer S, Jiménez-Ruiz A, Jungwirth H, Kainz K, Kontoyiannis DP, Ludovico P, Manon S, Martegani E, Mazzoni C, Megeney LA, Meisinger C, Nielsen J, Nyström T, Osiewacz HD, Outeiro TF, Park HO, Pendl T, Petranovic D, Picot S, Polčic P, Powers T, Ramsdale M, Rinnerthaler M, Rockenfeller P, Ruckenstuhl C, Schaffrath R, Segovia M, Severin FF, Sharon A, Sigrist SJ, Sommer-Ruck C, Sousa MJ, Thevelein JM, Thevissen K, Titorenko V, Toledano MB, Tuite M, Vögtle FN, Westermann B, Winderickx J, Wissing S, Wölfl S, Zhang ZJ, Zhao RY, Zhou B, Galluzzi L, Kroemer G, Madeo F.

Microb Cell. 2018 Jan 1;5(1):4-31. doi: 10.15698/mic2018.01.607. Review.

45.

Lysosome-targeting agents in cancer therapy.

Kroemer G, Galluzzi L.

Oncotarget. 2017 Oct 3;8(68):112168-112169. doi: 10.18632/oncotarget.21451. eCollection 2017 Dec 22.

46.

Everybody In! No Bouncers at Tumor Gates.

Vitale I, Galluzzi L.

Trends Genet. 2018 Feb;34(2):85-87. doi: 10.1016/j.tig.2017.12.006. Epub 2017 Dec 23.

PMID:
29277455
47.

Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.

Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S.

Semin Cancer Biol. 2018 Oct;52(Pt 2):125-134. doi: 10.1016/j.semcancer.2017.12.007. Epub 2017 Dec 16. Review.

PMID:
29258856
48.

Fighting Resilient Cancers with Iron.

Chen JJ, Galluzzi L.

Trends Cell Biol. 2018 Feb;28(2):77-78. doi: 10.1016/j.tcb.2017.11.007. Epub 2017 Dec 7. Review.

PMID:
29223642
49.

Mitochondrial metabolism and cancer.

Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L.

Cell Res. 2018 Mar;28(3):265-280. doi: 10.1038/cr.2017.155. Epub 2017 Dec 8. Review.

50.

Trial watch: DNA-based vaccines for oncological indications.

Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L.

Oncoimmunology. 2017 Nov 20;6(12):e1398878. doi: 10.1080/2162402X.2017.1398878. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center